IGF-1 DES — Benefits, Dosage & Where to Buy
Research Overview
IGF-1 DES (Des(1-3) IGF-1) is a truncated version of IGF-1 missing the first 3 amino acids of the N-terminus. This modification dramatically reduces binding to IGF-binding proteins (IGFBPs), making it approximately 10x more potent than native IGF-1 at the receptor level. However, unlike IGF-1 LR3, it retains a short half-life (~20-30 minutes).
IGF-1 DES is particularly potent for local/site-specific research applications due to its high bioactivity and short systemic duration. Its brief half-life limits systemic effects while allowing concentrated activity at the injection site.
Key Research Findings
- •~10x more potent than native IGF-1 due to reduced IGFBP binding
- •Short half-life (~20-30 min) limits systemic effects — useful for local/site-specific research
- •Potent stimulator of muscle protein synthesis and satellite cell activation
- •More site-specific than IGF-1 LR3 which has systemic distribution
Research Dosage Protocols
IGF-1 DES is supplied as lyophilized powder. Research doses are typically 20-50 mcg administered locally (intramuscular) due to its short half-life and high potency.
For research reference only. Not medical advice. Not for human consumption.
Published Research (2 studies)
- [1]
- [2]
Links go to PubMed (NIH National Library of Medicine). PeptideVerdict is not affiliated with these studies.
Price Comparison (2 products from 2 vendors)
| Vendor | Price | Stock |
|---|---|---|
| Swiss Chems | $55.95 $55.95/mg 1mg vial | In Stock |
| Pure Rawz | $109.93 $109.93/mg 1mg vial | In Stock |
Frequently Asked Questions
What is IGF-1 DES?
IGF-1 DES is a truncated IGF-1 10x more potent than native form. Its short half-life makes it ideal for site-specific research applications.
How does IGF-1 DES compare to IGF-1 LR3?
IGF-1 DES has higher acute potency but a much shorter half-life (minutes vs hours). DES is better for localized effects; LR3 provides sustained systemic activity.